ISTH 2020 Congress
Venous Thromboembolism and Cardioembolism » Atrial Fibrillation
Theme Navigation
- ISTH 2020 Congress
- Venous Thromboembolism and Cardioembolism
- Atrial Fibrillation
- Venous Thromboembolism and Cardioembolism
Abstract Number: PB2086
An observational Study of INR Control and Bleeding Events, According to European Society of Cardiology (ESC) Guidelines, in Non-valvular Atrial Fibrillation (NVAF) Stratified by Male and Female Sex
Abstract Number: PB2074
Anticoagulant Management Strategies in Cancer Patients with Atrial Fibrillation in Daily Clinical Practice
Abstract Number: PB2055
Anticoagulation in Non-Valvular Atrial Fibrillation: Old or New Friends?
Abstract Number: PB2069
Anticoagulation Resumption After Intracerebral Hemorrhage in Two Cohorts of Patients Treated with Vitamin K Antagonists and Direct Oral Anticoagulants
Abstract Number: PB2057
Assessment and Predictors of Inappropriate Dose of Direct Oral Anticoagulants
Abstract Number: PB2080
Association of Body Mass Index (BMI) with Bleeding Events in Patients Taking Oral Anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE)
Abstract Number: PB2060
Association of Clinical Risk Factors and Biomarkers with Thromboembolism, Major Bleeding, and All-Cause Death in Patients with Atrial Fibrillation in a Tertiary Care Setting
Abstract Number: PB2088
Atrial Fibrillation Treated with Warfarin at an Academic Medical Center: The Potential Impact of Direct Oral Anticoagulants on Future Management
Abstract Number: PB2079
Beyond the Registry: A Nuanced Evaluation of Real World Anticoagulation for Nonvalvular Atrial Fibrillation Patients at a Tertiary Care Center
Abstract Number: PB2049
Characterization of VKA Control in Patients with Thrombotic and Major Hemorrhagic Events in Anticoagulation Hematology Units: Results from the EVENTHO Study
Abstract Number: PB2040
Clinical Case: Reversal of Dabigatran Levels in Patients with Renal Insufficiency that Have Required the use of Idarucizumab
Abstract Number: PB2064
Clinical Outcomes for Patients of High Body Weight on Apixaban or Rivaroxaban
Abstract Number: PB2085
Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation
Abstract Number: PB/LB03
Differences in Outcomes between Real-World vs Clinical Trial in Atrial Fibrillation and Chronic Kidney Disease
Abstract Number: PB2051
Differences in Treatment and Outcomes in Recently Diagnosed Atrial Fibrillation between the Netherlands and Belgium: Results from the GARFIELD-AF Registry
Abstract Number: PB2062
Differential Effect of Direct Oral Anticoagulants (DOACs) on Thrombin Generation and Clot Lysis in Patients with Non Valvular Atrial Fibrillation (AF) and Venous Thromboembolism (VTE)
Abstract Number: PB2054
Effect of Patient and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) Study
Abstract Number: PB2068
Emergency Room Access of Patients on DOACs: A Six Years Single Center Experience
Abstract Number: PB2052
Factor V Leiden Is Associated with Atrial Fibrillation, but Not Ischemic Stroke in Atrial Fibrillation. The Tromsø Study
Abstract Number: PB2065
Fatal Intracerebral Hemorrhage in a Patient on Warfarin: A Case Report